ST. LOUIS (Map) - ST. LOUIS, May 9 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that its participation at Heart Rhythm 2008 reflects the broad market leadership it has achieved as the only provider of fully automated, remote navigation technology for cardiac ablation. Of the 96 core curriculum sessions that represent the principal scientific content of the conference, 90% include presentations by physicians from institutions that have already purchased or ordered a Niobe(R) Magnetic Navigation system. Stereotaxis customers are presenting in all 33 sessions related to ablation techniques. More than 30 presentations that feature clinical applications of Stereotaxis technology, in all four chambers of the heart, will be delivered through the core curriculum, abstracts and poster sessions.

For instance, Marcus Wharton, MD will present on magnetic field-guided ablation for complex arrhythmias at 1:35 pm PDT on May 16; from the lab of Jeremy Ruskin, MD, at Massachusetts General Hospital,

With this evidence of broad clinical utility as a backdrop, Stereotaxis plans to highlight the simplicity, safety, and efficacy that are enabled by its magnetic navigation and information management systems in several additional settings:

    o "The Integrated EP Lab: The Future of Complex Arrhythmia Ablation" --
      This accredited symposium sponsored by NACCME with educational support
      from Stereotaxis, Biosense Webster and Siemens Medical, will feature
      Carlo Pappone, MD, PhD presenting on information management and remote
      connectivity, Karl-Heinz Kuck, MD addressing magnetic navigation and
      catheter / tissue interface, and Andrea Natale, MD discussing ablation
      tools and technologies for ventricular tachycardia.
    o "Meet the Expert" Seminars -- In the Stereotaxis Mobile EP Lab,
      Booth # 304, leading clinical experts in electrophysiology and cardiac
      rhythm management will be available to discuss their experiences with
      remote magnetic navigation and advanced information management.
      Drs. Chaudhry, Dell'Orfano and Orlov will be presenting case data from
      10:00 to 11:30 am on Thursday, May 15, and Drs. Lakireddy and Tomassoni
      will present from 3:00 to 4:00 that afternoon.  On Friday, May 16 from
      10:00 to 11:30 am, participating clinicians include Dr. Ramaswamy and
      Profs. Pappone and Saoudi, and from 3:00 to 4:00 that afternoon,
      Prof. Kuck and Dr. Sacher.
    o Test Drive the Odyssey Network -- The Odyssey Network connects the
      growing installed base of EP labs, within and between hospitals, and
      Stereotaxis recently highlighted the first ever bi-directional live case
      transmission and training course conducted via the Stereotaxis Odyssey
      Network.  To experience the Odyssey Network's groundbreaking
      connectivity first-hand, visitors can use the consolidated display of
      the Odyssey Workstation installed in Stereotaxis' Booth # 304, to
      remotely navigate a catheter in a beating heart phantom with a Niobe
      System located at Stereotaxis' St. Louis, Missouri headquarters.
    o Introducing the Odyssey Cinema(TM) -- In addition to the remote
      networking capabilities of the Odyssey platform on display in
      Booth # 304, Stereotaxis will be demonstrating Odyssey's new archiving
      and procedure recording product, Odyssey Cinema.  Odyssey Cinema enables
      physicians to receive a real-time high definition view of a procedure
      from any point in the network of installed Odyssey Systems.  It also
      includes a powerful archiving capability that will allow clinicians to
      store and replay entire procedures or segments of procedures, thereby
      providing them with a significant new tool for clinical collaboration,
      remote consultation, and training.
    o Previewing Navigant 3.0 -- Navigant 3.0 is the next generation software
      for Niobe focused on simplification, automation, and enhanced
      integration.  New capabilities include automatic registration with x-ray
      and mapping systems, enhanced automation features, and re-targeting to
      compensate for movement.  Stereotaxis believes that, particularly when
      used in combination with Odyssey, Navigant 3.0 will significantly
      advance EP lab productivity and procedural workflow efficiency.

"With its Niobe Magnetic Navigation and Odyssey information management systems, Stereotaxis has built a powerful platform to advance the practice of electrophysiology well into the future, and we are confident that it will continue to transform interventional medicine in important ways," said Bevil Hogg, CEO of Stereotaxis. "We are delighted to see how pervasive a role Stereotaxis' platform is playing at Heart Rhythm 2008, fully independent of our own corporate initiatives and programs, and we view this as a profound endorsement of the simplicity, safety and efficacy of the Niobe system, as approximately 15,000 procedures have proven in every chamber of the heart. It is our belief that clinicians and patients will always seek out the safest alternative. We are committed to meeting this expectation of our customers, and recognize that this is our surest route to success."

Heart Rhythm 2008, the Heart Rhythm Society's 29th Annual Scientific Sessions, will be held at the Moscone Center in San Francisco from May 14 through May 17, 2008.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.